Ascendis Pharma (ASND) Misses Q3 EPS by 48c

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR2.88), EUR0.48 worse than the analyst estimate of (EUR2.40). Revenue for the quarter came in at EUR48.03 million versus the consensus estimate of EUR48.91 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Ascendis Pharma (ASND) PT Raised to $360 at Citi